Even if no data on the expression of miR-708 and its potential role in 4T1, TUBO, and BALB-neuT tumors are currently available, they can be easily obtained and used to evaluate the possibility of testing combinatorial treatments also in immunocompetent preclinical models of TNBC- and HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.